104 filings
8-K
RGRXD
Regenerx Biopharmaceuticals Inc
7 Aug 23
Submission of Matters to a Vote of Security Holders
3:57pm
8-K
RGRXD
Regenerx Biopharmaceuticals Inc
10 Jul 23
Entry into a Material Definitive Agreement
5:19pm
8-K
RGRXD
Regenerx Biopharmaceuticals Inc
20 Jun 23
Entry into a Material Definitive Agreement
5:38pm
8-K
RGRXD
Regenerx Biopharmaceuticals Inc
15 Nov 21
2021 Annual Stockholders Meeting
2:55pm
8-K
RGRXD
Regenerx Biopharmaceuticals Inc
22 Jul 21
Regulation FD Disclosure
5:00pm
8-K
xqmmc yhqcj5ins6rf
1 Jul 21
Entry into a Material Definitive Agreement
3:43pm
8-K
503 qwy9yt
14 May 21
RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome
3:07pm
8-K
vu9 naswx
19 Mar 21
RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial
12:55pm
8-K
a4s1zn5gqzmn7tvih2p
21 Oct 20
Entry into a Material Definitive Agreement
4:19pm
8-K
umwsi
13 Oct 20
RegeneRx Expects to Complete Short-Term Financing While Awaiting Completion of Phase 3 Clinical Trial for Dry Eye Syndrome
7:00am
8-K
jm041g3
30 Sep 19
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
op5wmj805
5 Mar 19
Entry into a Material Definitive Agreement
4:53pm
8-K
4y8jox2nc 4g9kz1hz90
15 Jun 18
Submission of Matters to a Vote of Security Holders
3:50pm
8-K
vsn5f6ctfk
25 Apr 18
Other Events
4:29pm
8-K
8da j89q83t
31 Aug 17
RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia
12:00am
8-K
730ecrjkhli6j5jrbzlv
13 Mar 17
Regulation FD Disclosure
12:00am
8-K
xvvx37oz 48re
2 Nov 16
Submission of Matters to a Vote of Security Holders
12:00am
8-K
mwbrf 6zo
12 Sep 16
Rodman & Renshaw 18 th Annual Global Investment Conference September 2016
12:00am
8-K
i8jjqjywp4p7
1 Jul 16
RegeneRx Announces $1.75 Million Private Placement
12:00am
8-K
fscct
29 Sep 15
Submission of Matters to a Vote of Security Holders
12:00am